Robert Burns
H.C. Wainwright & Co, LLC, Research Division
Awesome. So maybe let’s just start from a high level. For investors who may be newer to the Nurix story, can you provide a brief overview of the company, the platform and your pipeline today?
Arthur Sands
CEO, President & Director
Yes. So we’re focused on targeted protein degradation, which is a new small molecule approach to actually removing protein targets, disease targets from the cells via the ubiquitin proteasome system. So removal, targeted removal of the protein, which gets a more thorough hit on the target compared to inhibition.
So our lead program is BTK, a BTK degrader called bexobrutideg, recently just signed a great deal with Roche, which I’m sure we’ll talk about for CLL, chronic lymphocytic leukemia and non-Hodgkin’s lymphomas, where, again, we’re removing the BTK protein, and we get a more thorough and deeper efficacy response, can address resistance mutations to inhibitors. The inhibitor class is $10 billion a year class, but a lot of resistance mutations coming up.
So degradation removes that with Bexdeg, as we call it for short. And then we have a whole inflammation program, partially with Bexdeg, again, with Roche, but also our STAT6 program with
Credit: Source link
